Not logged in...
About USC Norris
Research
Patient Care
CISO
Search Trials
FAQ - Trials
Contact Us - Trials
Membership
Education
Shared Resources
Support USC Norris
Outreach
Login/Logout
Contact USC Norris
Support Us
Donate
Menu
USC Norris
»
Clinical Trials
Trial 6G-15-3
Study of Immunotherapy in Newly Diagnosed Glioblastoma: A Phase III randomized double-blind, controlled study of ICT-107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy
Type:
Treatment
Phase:
Phase III
Status:
Not Open (Closed)
Treatments:
Biological Response Modifier, Chemotherapy: Systemic, Radiation: External, Vaccine
Randomized:
Yes
USC Satellite Location:
None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:
Naveed Wagle, M.D.
Other Trial Staff:
Aida Lozada, D.M., Aida Lozada, Coordinator
Staff may
log in
to see study documents.
Click here to see trial eligibility criteria and further details at ClinicalTrials.gov
For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or
clinical.trials@med.usc.edu
.
To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.